Literature DB >> 24857519

Melatonin and dopamine as biomarkers to optimize treatment in phenylketonuria: effects of tryptophan and tyrosine supplementation.

Shoji Yano1, Kathryn Moseley1, Colleen Azen2.   

Abstract

OBJECTIVE: To determine whether additional supplementation of tryptophan (Trp) and tyrosine (Tyr) improve serotonin and dopamine metabolism in individuals with phenylketonuria treated with large neutral amino acid (LNAA) tablets. STUDY
DESIGN: Ten adult individuals with phenylketonuria participated in a randomized, double-blind, placebo-controlled cross-over study consisting of three 3-week phases: washout, treatment with LNAA tablets plus supplementation with either Trp and Tyr tablets or placebo, and LNAA tablets plus the alternate supplementation. An overnight protocol to measure blood melatonin, a serotonin metabolite in the pinealocytes, and urine 6-sulfatoxymelatonin and dopamine in first-void urine specimens was conducted after each phase.
RESULTS: Serum melatonin and urine 6-sulfatoxymelatonin and dopamine levels were increased in the LNAA phase (LNAA plus placebo) compared with the washout phase. Serum melatonin and urine 6-sulfatoxymelatonin were not increased in the active phase (LNAA plus Trp + Tyr) compared with the LNAA phase, although plasma Trp:LNAA was increased compared with the LNAA phase. Among 7 subjects with a plasma Trp/LNAA >0.03, a negative correlation between urine 6-sulfatoxymelatonin and plasma phenylalanine levels was observed (r = -0.072). Urine dopamine levels and plasma Tyr:LNAA were increased in the active phase compared with the LNAA phase.
CONCLUSION: Melatonin levels were not increased with the higher dose of Trp supplementation, but dopamine levels were increased with the higher dose of Tyr supplementation. Serotonin synthesis appears to be suppressed by high phenylalanine levels at the Trp hydroxylase level.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24857519      PMCID: PMC8889885          DOI: 10.1016/j.jpeds.2014.03.061

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  29 in total

1.  Measurement of neurotransmitter metabolites in the cerebrospinal fluid of phenylketonuric patients under dietary treatment.

Authors:  A B Burlina; L Bonafé; V Ferrari; A Suppiej; F Zacchello; A P Burlina
Journal:  J Inherit Metab Dis       Date:  2000-06       Impact factor: 4.982

2.  ON THE MECHANISM OF THE BRAIN SEROTONIN DEPLETION IN EXPERIMENTAL PHENYLKETONURIA.

Authors:  A YUWILER; E GELLER; G G SLATER
Journal:  J Biol Chem       Date:  1965-03       Impact factor: 5.157

3.  Increased neurotransmitter biosynthesis in phenylketonuria induced by phenylalanine restriction or by supplementation of unrestricted diet with large amounts of tyrosine.

Authors:  C Lykkelund; J B Nielsen; H C Lou; V Rasmussen; A M Gerdes; E Christensen; F Güttler
Journal:  Eur J Pediatr       Date:  1988-12       Impact factor: 3.183

4.  Tyrosine monitoring in children with early and continuously treated phenylketonuria: results of an international practice survey.

Authors:  Rachael Sharman; Karen A Sullivan; Ross McD Young; James J McGill
Journal:  J Inherit Metab Dis       Date:  2010-09-30       Impact factor: 4.982

5.  Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: a post-mortem study.

Authors:  Peter Zill; Andreas Büttner; Wolfgang Eisenmenger; Hans-Jürgen Möller; Manfred Ackenheil; Brigitta Bondy
Journal:  J Psychiatr Res       Date:  2005-07-14       Impact factor: 4.791

6.  Psychiatric symptoms and disorders in phenylketonuria.

Authors:  V L Brumm; D Bilder; S E Waisbren
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

7.  Effect of metals and phenylalanine on the activity of human tryptophan hydroxylase-2: comparison with that on tyrosine hydroxylase activity.

Authors:  Shintaro Ogawa; Hiroshi Ichinose
Journal:  Neurosci Lett       Date:  2006-04-11       Impact factor: 3.046

8.  Characterization of tryptophan high affinity transport system in pinealocytes of the rat. Day-night modulation.

Authors:  C I Gutiérrez; M Urbina; F Obregion; J Glykys; L Lima
Journal:  Amino Acids       Date:  2003-07       Impact factor: 3.520

9.  Association of tryptophan hydroxylase gene polymorphism with depression, anxiety and comorbid depression and anxiety in a population-based sample of postpartum Taiwanese women.

Authors:  H S Sun; H-W Tsai; H-C Ko; F-M Chang; T-L Yeh
Journal:  Genes Brain Behav       Date:  2004-12       Impact factor: 3.449

10.  Large neutral amino acid supplementation increases melatonin synthesis in phenylketonuria: a new biomarker.

Authors:  Shoji Yano; Kathryn Moseley; Colleen Azen
Journal:  J Pediatr       Date:  2012-11-16       Impact factor: 4.406

View more
  5 in total

1.  Nutritional status in patients with phenylketonuria using glycomacropeptide as their major protein source.

Authors:  A Pinto; M F Almeida; P C Ramos; S Rocha; A Guimas; R Ribeiro; E Martins; A Bandeira; A MacDonald; J C Rocha
Journal:  Eur J Clin Nutr       Date:  2017-04-12       Impact factor: 4.016

2.  Tyrosine supplementation for phenylketonuria.

Authors:  Tracey Remmington; Sherie Smith
Journal:  Cochrane Database Syst Rev       Date:  2021-01-04

3.  Patient's thoughts and expectations about centres of expertise for PKU.

Authors:  A M J van Wegberg; A MacDonald; D Abeln; T S Hagedorn; E Lange; F Trefz; D van Vliet; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2021-01-06       Impact factor: 4.123

4.  Evaluation of Tetrahydrobiopterin Therapy with Large Neutral Amino Acid Supplementation in Phenylketonuria: Effects on Potential Peripheral Biomarkers, Melatonin and Dopamine, for Brain Monoamine Neurotransmitters.

Authors:  Shoji Yano; Kathryn Moseley; Xiaowei Fu; Colleen Azen
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

5.  The Benefit of Large Neutral Amino Acid Supplementation to a Liberalized Phenylalanine-Restricted Diet in Adult Phenylketonuria Patients: Evidence from Adult Pah-Enu2 Mice.

Authors:  Danique van Vliet; Els van der Goot; Wiggert G van Ginkel; Martijn H J R van Faassen; Pim de Blaauw; Ido P Kema; Aurora Martinez; M Rebecca Heiner-Fokkema; Eddy A van der Zee; Francjan J van Spronsen
Journal:  Nutrients       Date:  2019-09-19       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.